Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top

JOIN OUR EFFORTS TO

kill cancer with viruses

by launching a science company.
We developed targeted cancer therapies to avoid the unfortunate side effects of traditional treatments like surgery and chemotherapy. Tumours are composed of such diverse cell populations, however, that targeted therapies fail to kill all the cancer, resulting in relapse.
What if we could use something that moves faster than cancer, and that relies on the very characteristics that make tumour cells cancerous to survive? Enter the oncolytic virus: these have been the subject of niche oncology research for many years, but have struggled to spread through and clear tumours before they are cleared by the patient’s immune system.
Dr George Tetley is leading our efforts in this space using the latest developments in immune and synthetic biology to develop curative viral therapies for cancer. He’s now looking for a team of scientists who want to be entrepreneurs and turn ideas into reality.
our offer
We provide a low-risk opportunity to experience scientific entrepreneurship first-hand, before taking the leap as a full-time cofounder. We’ll first engage with you on an online/remote basis to get to know you better (and for you to get to know us), followed by an opportunity to join full-time as a cofounder, earning a stipend until the project reaches our investment criteria. At this point we’ll invest £50k to build the technical proof-of-concept, with up to £450k in follow-on funding available.
Our network of industry and funding partners ensures that teams in our portfolio get unfair access to pilot trials, partnerships and additional funding.
the ideal profile for this opportunity
We developed targeted cancer therapies to avoid the unfortunate side effects of traditional treatments like surgery and chemotherapy. Tumours are composed of such diverse cell populations, however, that targeted therapies fail to kill all the cancer, resulting in relapse.
What if we could use something that moves faster than cancer, and that relies on the very characteristics that make tumour cells cancerous to survive? Enter the oncolytic virus: these have been the subject of niche oncology research for many years, but have struggled to spread through and clear tumours before they are cleared by the patient’s immune system.
Dr George Tetley is leading our efforts in this space using the latest developments in immune and synthetic biology to develop curative viral therapies for cancer. He’s now looking for a team of scientists who want to be entrepreneurs and turn ideas into reality.
our offer
We provide a low-risk opportunity to experience scientific entrepreneurship first-hand, before taking the leap as a full-time cofounder. We’ll first engage with you on an online/remote basis to get to know you better (and for you to get to know us), followed by an opportunity to join full-time as a cofounder, earning a stipend until the project reaches our investment criteria. At this point we’ll invest £50k to build the technical proof-of-concept, with up to £450k in follow-on funding available.
Our network of industry and funding partners ensures that teams in our portfolio get unfair access to pilot trials, partnerships and additional funding.
the ideal profile for this opportunity

text

a PhD coupled with professional experience in either or both areas below:

 

  • Immuno-oncology (tumor biology, phenotypic characterisation of cancer)

 

  • Virology (viral design and production, understanding the mechanics of viruses, ideally experience with oncolytic virus)

text

text

a PhD coupled with professional experience in either or both areas below:

 

  • Immuno-oncology (tumor biology, phenotypic characterisation of cancer)

 

  • Virology (viral design and production, understanding the mechanics of viruses, ideally experience with oncolytic virus)

text

Interviews ongoing

Interviews ongoing

About George

George Tetley is looking at the immuno-oncology field for opportunities to start-up companies that will improve outcomes for cancer patients. After really enjoying his research project in immune cell metabolic activation at Trinity College, Dublin he went on to study for a PhD at Cambridge. Over the next four years he discovered and brought forward a peptide active against a commonly dysregulated cancer pathway, which has now progressed into an Astrazeneca collaboration. George is passionate about the translation of scientific research into practice and as such joined DSV, which aims to accelerate this process. Immuno-oncology is booming and is promising revolutions in cancer care, which is something that should get us all excited. Get in touch to learn more via george@dsv.io 

About George

George Tetley is looking at the immuno-oncology field for opportunities to start-up companies that will improve outcomes for cancer patients. After really enjoying his research project in immune cell metabolic activation at Trinity College, Dublin he went on to study for a PhD at Cambridge. Over the next four years he discovered and brought forward a peptide active against a commonly dysregulated cancer pathway, which has now progressed into an Astrazeneca collaboration. George is passionate about the translation of scientific research into practice and as such joined DSV, which aims to accelerate this process. Immuno-oncology is booming and is promising revolutions in cancer care, which is something that should get us all excited. Get in touch to learn more via george@dsv.io